Nucala Resources

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.¹

Patient support booklet

An informative guide for patients prescribed
Nucala pre-filled pen or pre-filled syringe.

Paediatric patient support booklet

An informative guide for paediatric patients
prescribed Nucala pre-filled pen or pre-filled
syringe.

Pre-filled pen and pre-filled syringe demonstration devices are available for you to order to your practice.

YourNucala app

Alternative text

YourNucala provides your patients with the information they need at their fingertips to inject with confidence from home and helps guide them through their treatment journey.

Whether they’re new to self-administration of Nucala or they've been doing it for a while, the YourNucala app can support your patients' along the way. YourNucala offers eligible step-by-step administration guides, injection logs and injection reminders, as well as helps them stay on track with their treatment plan.

YourNucala may not be available in some areas. For information on access and how your patients could benefit from the app, please discuss with your local GSK Nucala contact.

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older¹.

The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in pre-filled pen, pre-filled syringe or as a lyophilised powder. The licensed dose of Nucala in children aged 6–11 years is 40mg SC regardless of weight, and is available as a lyophilised powder. The prefilled formulations are not indicated in 6-11 year olds.¹

References

  1. Nucala SmPC, 2020.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

© 2020 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

PM-GB-MPL-WCNT-200028 | November 2020